Is Astrana Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its current pricing relative to its fundamentals. The company appears to be overvalued based on key metrics, including a P/E ratio of 36, an EV to EBIT of 19.76, and a Price to Book Value of 1.90. In comparison, peers like Premier, Inc. and Select Medical Holdings Corp. show much lower P/E ratios of 11.29 and 7.26, respectively, highlighting the disparity in valuation.
Despite a recent strong performance with a 1-week return of 9.96% compared to the S&P 500's 1.70%, the longer-term outlook is concerning, as the stock has declined 47.84% over the past year while the S&P 500 gained 14.08%. This stark contrast reinforces the notion that Astrana Health, Inc. is currently overvalued in the market.